The 2024Q4 spike to 15.5% ROIC coincides with a negative gross margin (-17.5%) and a -0.01 asset turnover, which signals the figure was driven by abnormal non-operating items rather than operating performance, so it should not be treated as a durable return benchmark. On cleaner quarters, ROIC of roughly -2% to 2% versus ROE of -3.6% to 2.4% suggests minimal value creation on the $137M equity base; with debt-to-equity of only 0.17, the gap between ROE and ROIC is negligible, meaning leverage is neither amplifying nor suppressing returns. The improvement trajectory — from -2.6% in 2025Q1 to +1.8% in 2026Q2 — tracks gross margin recovery from 56.1% to 65.1%, implying margin rebuild, not capital efficiency (asset turnover still near 0.18), is the current driver. Compared to MiMedx's 42.3% ROIC in the same peer set, Anika's returns remain structurally depressed, and whether they can normalize above a cost-of-capital threshold warrants further investigation as volumes stabilize.

The DIO expansion from 125 days in 2025Q3 to 206 in 2026Q2 is the dominant working capital trend; interpreted alongside a rising asset turnover (0.15 to 0.18) and improving gross margin, it may indicate deliberate inventory pre-positioning ahead of a demand ramp, though a build of that magnitude against still-modest revenue also raises inventory risk if the projected volume fails to materialize. This interpretation aligns with the cash flow picture: working capital consumed $13.8M in 2026Q2 alone, which explains why $3.3M of net income still produced negative operating cash flow. DSO holding steady at 74-78 days across ten quarters suggests customer payment discipline is stable, while DPO drifting up from 21 days (2024Q3) to 50 days shows modest supplier financing extension, but neither is large enough to offset the inventory drag. For a manufacturer of regenerative biomaterials, a CCC this far above typical device peers (which commonly run under 150 days) is a meaningful capital drag that investors should monitor closely against inventory turnover trends in coming quarters.

Interest coverage is not reported in the data set, so debt service comfort cannot be directly evaluated; however, with a current ratio of 4.48 and cash holdings around $38M versus $23M of debt, the company's capacity to service obligations appears comfortable on a liquidity basis alone, though cash is down 44% from $68.6M in 2024Q1. Debt-to-EBITDA showed 13.36x in 2025Q4 and 5.23x in 2026Q2, a compression that reflects EBITDA recovery rather than debt reduction — a distinction that matters because the low leverage is only sustainable if the earnings rebound holds. Compared with peers like Novocure (0.85x D/E) and Lantheus (0.57x), Anika is among the least levered in the group, which suggests refinancing risk is minimal and the balance sheet retains ample capacity, but this comfort has not translated into positive free cash flow, which is the more relevant constraint on financial flexibility.

The spread between current (4.48) and quick (3.19) ratios implies roughly one-third of current assets sits in inventory, whose 206-day on-hand level would be difficult to monetize quickly under stress, so the true immediate-payment buffer is closer to the quick ratio and the $38.4M cash balance. Even under that stricter lens, cash covers total debt of ~$23M roughly 1.7 times and near-term operating losses several times over, so solvency stress appears distant. The concern is trajectory rather than position: cash has fallen from $68.6M to $38.4M while buybacks have consumed ~$30M across the ten-quarter window despite cumulative negative free cash flow, a deployment pattern that reduces the cushion faster than operations rebuild it. Relative to peers like AtriCure and Halozyme, whose leverage is higher but whose operations generate cash, Anika's liquidity advantage is real but may erode if negative FCF persists another two to three quarters, which is what the current ratio alone obscures.

The 8.18x forward EV/EBITDA sits below most profitable peers — Lantheus at 17.76x and Halozyme at 19.01x — but above MiMedx's 5.30x, which is reasonable if one accepts that Anika's mid-sixties gross margin (65.1% in 2026Q2) reflects a structurally improving product mix rather than a one-quarter normalization. The trailing P/E being negative while the forward P/E is ~20x embeds an assumption of a clean swing to sustained profitability; the 2026Q2 quarter (9.1% operating margin) supports direction, but the SG&A swing from $17.8M to $10.9M quarter-over-quarter suggests that profitability is not yet durably covered by fixed-cost discipline. A 2.52x P/S multiple against a 10.1% net margin implies the market is not paying for hyper-growth, but rather for margin repair on a roughly flat revenue base; the 65x P/FCF is the multiple that most starkly captures how little of the implied earnings has converted to cash. Against a P/B of 2.13x with a 2.4% ROE, the valuation clearly prices forward returns well above current ones, leaving limited margin of safety if the recovery stalls.